The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the diabetes prevention trial-type 1

Diabetes

Volumn 61, Issue 6, 2012, Pages 1331-1337

  Sosenko, Jay M ^a   Skyler, Jay S ^a   Herold, Kevan C ^b   Palmer, Jerry P ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; INSULIN ZINC SUSPENSION; PLACEBO; RECOMBINANT HUMAN INSULIN;

CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLISM; ORAL GLUCOSE TOLERANCE TEST; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; GLUCOSE TOLERANCE TEST; HUMANS;

EID: 84861868035     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1660     Document Type: Review

References (50)

1. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2:1363-1365 (Pubitemid 12239439)
2. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991;34:93-102
3. Chase HP, Voss MA, Butler-Simon N, Hoops S, O'Brien D, Dobersen MJ. Diagnosis of pre-type I diabetes. J Pediatr 1987;111:807-812 (Pubitemid 18019150)
4. Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS. First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. N Engl J Med 1985;313: 461-464 (Pubitemid 15015072)
5. Ginsberg-Fellner F, Witt ME, Franklin BH, et al. Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus. JAMA 1985;254:1469-1472 (Pubitemid 15239327)
6. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-1691
7. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
8. Gale EA, Bingley PJ, Emmett CL, Collier T; The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1. Lancet 2004;363:925-931
9. Triolo TM, Chase HP, Barker JM; DPT-1 Study Group. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care 2009;32: 769-773
10. Sosenko J, Palmer JP, Greenbaum CJ, et al. Diabetes Prevention Trial- Type 1 Study Group. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29: 643-649 (Pubitemid 44115367)
11. O'Leary LA, Dorman JS, LaPorte RE, et al. Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies? Diabetes Res Clin Pract 1991;14:183-190
12. Komulainen J, Knip M, Lounamaa R, et al.; Childhood Diabetes in Finland Study Group. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. Diabet Med 1997;14:532-537 (Pubitemid 27298812)
13. Faber OK, Binder C. B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 1977;13:263-268 (Pubitemid 8109393)
14. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Diabetes Prevention Trial- Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620-625
15. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318:1231-1239
16. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-433 (Pubitemid 38174559)
17. Barker JM, McFann K, Harrison LC, et al.; DPT-1 Study Group. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr 2007;150:31-36, e6
18. Knip M, Vähäsalo P, Karjalainen J, Lounamaa R, Åkerblom HK; Childhood Diabetes in Finland Study Group. Natural history of preclinical IDDM in high risk siblings. Diabetologia 1994;37:388-393 (Pubitemid 24113571)
19. Stene LC, Barriga K, Hoffman M, et al. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006;7:247-253 (Pubitemid 44593924)
20. Rosenbloom AL, Hunt SS, Rosenbloom EK, Maclaren NK. Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulindependent diabetes. Diabetes 1982;31:385-387 (Pubitemid 12152722)
21. Tarn AC, Smith CP, Spencer KM, Bottazzo GF, Gale EA. Type I (insulin dependent) diabetes: a disease of slow clinical onset? Br Med J (Clin Res Ed) 1987;294:342-345 (Pubitemid 17007401)
22. Beer SF, Heaton DA, Alberti KG, Pyke DA, Leslie RD. Impaired glucose tolerance precedes but does not predict insulin-dependent diabetes mellitus: a study of identical twins. Diabetologia 1990;33:497-502 (Pubitemid 20254873)
23. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in The Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
24. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010;59:679-685
25. Ludvigsson J, Heding LG, Larsson Y, Leander E. C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestation at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977;66:177-184 (Pubitemid 8107346)
26. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes. N Engl J Med 1989;350:550-555
27. Törn C, Landin-Olsson M, Lernmark A, et al. Prognostic factors for the course of β cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-4623 (Pubitemid 32157642)
28. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
29. Ortqvist E, Björk E, Wallensteen M, et al. Temporary preservation of β-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004;27:2191-2197 (Pubitemid 39167184)
30. Brown RJ, Sinaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 2008;31:1403-1404
31. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009;32:1839-1844
32. Petrone A, Spoletini M, Zampetti S, et al. The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual β-cell function and worse metabolic control. Diabetes Care 2008;31:1214-1218
33. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Diabetes Prevention Trial- Type 1 Study Group. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:1603-1607
34. Sosenko JM, Skyler JS, Krischer JP, et al. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Glucose excursions between states of glycemia with progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2010;59:2386-2389
35. Sosenko J, Palmer JP, Greenbaum CJ, et al. the Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes. Diabetes Care 2007;30:38-42 (Pubitemid 46052498)
36. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18:192-200 (Pubitemid 34778382)
37. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP. the Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007;30:2314-2320 (Pubitemid 47359040)
38. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667 (Pubitemid 40022398)
39. Mrena S, Virtanen SM, Laippala P, et al. the Childhood Diabetes in Finland Study Group. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006;29:662-667 (Pubitemid 44115370)
40. Bingley PJ, Mahon JL, Gale EA. the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-150
41. Yalow RS, Glick SM, Roth J, Berson SA. Plasma insulin and growth hormone levels in obesity and diabetes. Ann N Y Acad Sci 1965;131:357-373
42. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967;41:1549-1557
43. Yki-Yarvinen H, Koivisto VA. Natural course of insulin resistance in type 1 diabetes. N Engl J Med 1986;315:224-230 (Pubitemid 16097124)
44. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st year after diagnosis. Diabetes Care 1992;15:66-74
45. Sosenko JM, Krischer JP, Palmer JP, et al. Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody positive participants in The Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:528-533
46. Sosenko JM, Skyler JS, Mahon J, et al. Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of the Diabetes Prevention Trial-Type 1 risk score (DPTRS) in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787
47. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836 (Pubitemid 36929351)
48. The Diabetes Control and Complications Trial Research Group. Effects of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128: 517-523
49. Pociot F, Ronnigen KS, Bergholdt R, et al. Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes evidence for polygenicity in man: Danish Study Group of Diabetes in Childhood. Autoimmunity 1994;19:169-178
50. Siljander HT, Simell S, Hekkala A, et al. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 2009;58:2835-2842